The possibilities of LOXL4 as a prognostic marker for carcinomas.
Carcinoma
LOXL4
Prognostic marker
Journal
Amino acids
ISSN: 1438-2199
Titre abrégé: Amino Acids
Pays: Austria
ID NLM: 9200312
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
16
05
2022
accepted:
25
09
2023
medline:
4
12
2023
pubmed:
10
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
Lysyl oxidase-like 4 (LOXL4), a member of lysyl oxidase family, is a copper and lysine tyrosylquinone-dependent amine oxidase that serves the role of catalyzing the cross-linking of elastin and collagen in the extracellular matrix. Numerous studies have shown a significant association between LOXL4 expression levels and tumor proliferation, migration, invasion and patients' prognosis and overall survival in different types of tumors. Here we review their relationship and the molecular pathogenesis behind them, aiming to explore the possibilities of LOXL4 as a prognostic marker for diverse carcinomas and provide some indications for further research in this field.
Identifiants
pubmed: 37814029
doi: 10.1007/s00726-023-03343-9
pii: 10.1007/s00726-023-03343-9
doi:
Substances chimiques
Protein-Lysine 6-Oxidase
EC 1.4.3.13
Amino Acid Oxidoreductases
EC 1.4.-
Collagen
9007-34-5
LOXL4 protein, human
EC 1.4.3.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1519-1529Subventions
Organisme : Natural Science Foundation of Guangdong Province, China
ID : 2018A030313664
Organisme : 2020 Li Ka Shing Foundation Cross-Disciplinary Research Grant
ID : 2020LKSFG09B
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
American Cancer Society, Inc. Cancer facts and figures 2020. Breast Statistics: American Cancer Society; 2020. . http://www.cancer.org .
Asuncion L, Fogelgren B, Fong KS, Fong SF, Kim Y, Csiszar K (2001) A novel human lysyl oxidase-like gene (LOXL4) on chromosome 10q24 has an altered scavenger receptor cysteine rich domain. Matrix Biology : Journal of the International Society for Matrix Biology 20(7):487–491. https://doi.org/10.1016/s0945-053x(01)00161-5
doi: 10.1016/s0945-053x(01)00161-5
pubmed: 11691588
Barker HE, Cox TR, Erler JT (2012) The rationale for targeting the LOX family in cancer. Nat Rev Cancer 12(8):540–552. https://doi.org/10.1038/nrc3319
doi: 10.1038/nrc3319
pubmed: 22810810
Bray F, Laversanne M, Weiderpass E, Soerjomataram I (2021) The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127(16):3029–3030. https://doi.org/10.1002/cncr.33587
doi: 10.1002/cncr.33587
pubmed: 34086348
Cao G, Tan B, Wei S, Shen W, Wang X, Chu Y, Rong T, Gao C (2020) Down-regulation of MBNL1-AS1 contributes to tumorigenesis of NSCLC via sponging miR-135a-5p. Biomedecine & Pharmacotherapie 125:109856. https://doi.org/10.1016/j.biopha.2020.109856
doi: 10.1016/j.biopha.2020.109856
Chai T, Shen Z, Zhang Z, Chen S, Gao L, Zhang P, Lin W, Kang M, Lin J (2020) LGR6 is a potential diagnostic and prognostic marker for esophageal squamous cell carcinoma. J Clin Lab Anal 34(4):e23121. https://doi.org/10.1002/jcla.23121
doi: 10.1002/jcla.23121
pubmed: 31917882
pmcid: 7171331
Chen M, Jin D, Wang B, Gou YJ, Dong XC (2020) Identification of miRNAs as prognostic factors for esophageal squamous cell carcinoma. Mathematical Biosciences and Engineering : MBE 17(3):2302–2309. https://doi.org/10.3934/mbe.2020122
doi: 10.3934/mbe.2020122
pubmed: 32233536
Choi SK, Kim HS, Jin T, Moon WK (2017) LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer. Oncotarget 8(7):11977–11989. https://doi.org/10.18632/oncotarget.14450
doi: 10.18632/oncotarget.14450
pubmed: 28060764
pmcid: 5355319
Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, Xiao J, Qian L, Zhao W, Liu Q, Zhang D, Wang Y, Zhang H, He Y, Zhu J (2014) miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Mol Cancer 13:234. https://doi.org/10.1186/1476-4598-13-234
doi: 10.1186/1476-4598-13-234
pubmed: 25311867
pmcid: 4200202
Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, Al-Shibli K, Donnem T, Busund LT, Bremnes RM (2014) Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer (amsterdam, Netherlands) 83(2):272–278. https://doi.org/10.1016/j.lungcan.2013.11.005
doi: 10.1016/j.lungcan.2013.11.005
pubmed: 24305009
Fan L, Cao Q, Liu J, Zhang J, Li B (2019) Circular RNA profiling and its potential for esophageal squamous cell cancer diagnosis and prognosis. Mol Cancer 18(1):16. https://doi.org/10.1186/s12943-018-0936-4
doi: 10.1186/s12943-018-0936-4
pubmed: 30674324
pmcid: 6343327
Finney J, Moon HJ, Ronnebaum T, Lantz M, Mure M (2014) Human copper-dependent amine oxidases. Arch Biochem Biophys 546:19–32. https://doi.org/10.1016/j.abb.2013.12.022
doi: 10.1016/j.abb.2013.12.022
pubmed: 24407025
pmcid: 5995473
Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet (london, England) 379(9822):1245–1255. https://doi.org/10.1016/s0140-6736(11)61347-0
doi: 10.1016/s0140-6736(11)61347-0
pubmed: 22353262
Görögh T, Weise JB, Holtmeier C, Rudolph P, Hedderich J, Gottschlich S, Hoffmann M, Ambrosch P, Csiszar K (2007) Selective upregulation and amplification of the lysyl oxidase like-4 (LOXL4) gene in head and neck squamous cell carcinoma. J Pathol 212(1):74–82. https://doi.org/10.1002/path.2137
doi: 10.1002/path.2137
pubmed: 17354256
Gross-Cohen M, Feld S, Naroditsky I, Nativ O, Ilan N, Vlodavsky I (2016) Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage. Oncotarget 7(16):22556–22565. https://doi.org/10.18632/oncotarget.8003
doi: 10.18632/oncotarget.8003
pubmed: 26968815
pmcid: 5008381
Hämäläinen ER, Jones TA, Sheer D, Taskinen K, Pihlajaniemi T, Kivirikko KI (1991) Molecular cloning of human lysyl oxidase and assignment of the gene to chromosome 5q23.3-31.2. Genomics 11(3):508–516. https://doi.org/10.1016/0888-7543(91)90057-l
doi: 10.1016/0888-7543(91)90057-l
pubmed: 1685472
Hata A, Lieberman J (2015) Dysregulation of microRNA biogenesis and gene silencing in cancer. Science Signaling. https://doi.org/10.1126/scisignal.2005825
doi: 10.1126/scisignal.2005825
pubmed: 25783160
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300. https://doi.org/10.3322/caac.20073
doi: 10.3322/caac.20073
pubmed: 20610543
Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100(23):1672–1694. https://doi.org/10.1093/jnci/djn389
doi: 10.1093/jnci/djn389
pubmed: 19033571
pmcid: 2639291
Ji Y, You Y, Wu Y, Wang M, He Q, Zhou X, Chen L, Sun X, Liu Y, Fu X, Kwan HY, Zuo Q, Luo R, Zhao X (2022) Overexpression of miR-328-5p influences cell growth and migration to promote NSCLC progression by targeting LOXL4. Annals of Translational Medicine 10(6):301. https://doi.org/10.21037/atm-22-345
doi: 10.21037/atm-22-345
pubmed: 35433959
pmcid: 9011230
Jourdan-Le Saux C, Le Saux O, Donlon T, Boyd CD, Csiszar K (1998) The human lysyl oxidase-related gene (LOXL2) maps between markers D8S280 and D8S278 on chromosome 8p21.2-p21.3. Genomics 51(2):305–307. https://doi.org/10.1006/geno.1998.5356
doi: 10.1006/geno.1998.5356
pubmed: 9722957
Jourdan-Le Saux C, Tomsche A, Ujfalusi A, Jia L, Csiszar K (2001) Central nervous system, uterus, heart, and leukocyte expression of the LOXL3 gene, encoding a novel lysyl oxidase-like protein. Genomics 74(2):211–218
doi: 10.1006/geno.2001.6545
pubmed: 11386757
Jourdan-Le Saux C, Tronecker H, Bogic L, Bryant-Greenwood GD, Boyd CD, Csiszar K (1999) The LOXL2 gene encodes a new lysyl oxidase-like protein and is expressed at high levels in reproductive tissues. J Biol Chem 274(18):12939–12944
doi: 10.1074/jbc.274.18.12939
pubmed: 10212285
Kagan HM, Trackman PC (1991) Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 5(3):206–210. https://doi.org/10.1165/ajrcmb/5.3.206
doi: 10.1165/ajrcmb/5.3.206
pubmed: 1680355
Kasashima H, Yashiro M, Okuno T, Miki Y, Kitayama K, Masuda G, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Sakurai K, Toyokawa T, Kubo N, Tanaka H, Muguruma K, Hirakawa K, Ohira M (2018) Significance of the Lysyl Oxidase Members Lysyl Oxidase Like 1, 3, and 4 in Gastric Cancer. Digestion 98(4):238–248. https://doi.org/10.1159/000489558
doi: 10.1159/000489558
pubmed: 30045039
Kenyon K, Modi WS, Contente S, Friedman RM (1993) A novel human cDNA with a predicted protein similar to lysyl oxidase maps to chromosome 15q24-q25. J Biol Chem 268(25):18435–18437
doi: 10.1016/S0021-9258(17)46643-9
pubmed: 7689553
Kim DJ, Lee DC, Yang SJ, Lee JJ, Bae EM, Kim DM, Min SH, Kim SJ, Kang DC, Sang BC, Myung PK, Park KC, Yeom YI (2008) Lysyl oxidase like 4, a novel target gene of TGF-beta1 signaling, can negatively regulate TGF-beta1-induced cell motility in PLC/PRF/5 hepatoma cells. Biochem Biophys Res Commun 373(4):521–527. https://doi.org/10.1016/j.bbrc.2008.06.071
doi: 10.1016/j.bbrc.2008.06.071
pubmed: 18586005
Leo C, Cotic C, Pomp V, Fink D, Varga Z (2018) Overexpression of Lox in triple-negative breast cancer. Ann Diagn Pathol 34:98–102. https://doi.org/10.1016/j.anndiagpath.2018.03.009
doi: 10.1016/j.anndiagpath.2018.03.009
pubmed: 29661738
Li R, Wang Y, Zhang X, Feng M, Ma J, Li J, Yang X, Fang F, Xia Q, Zhang Z, Shang M, Jiang S (2019) Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Mol Cancer 18(1):18. https://doi.org/10.1186/s12943-019-0948-8
doi: 10.1186/s12943-019-0948-8
pubmed: 30704479
pmcid: 6354392
Li RK, Zhao WY, Fang F, Zhuang C, Zhang XX, Yang XM, Jiang SH, Kong FZ, Tu L, Zhang WM, Yang SL, Cao H, Zhang ZG (2015) Lysyl oxidase-like 4 (LOXL4) promotes proliferation and metastasis of gastric cancer via FAK/Src pathway. J Cancer Res Clin Oncol 141(2):269–281. https://doi.org/10.1007/s00432-014-1823-z
doi: 10.1007/s00432-014-1823-z
pubmed: 25216702
Li TY, Xu LY, Wu ZY, Liao LD, Shen JH, Xu XE, Du ZP, Zhao Q, Li EM (2012) Reduced nuclear and ectopic cytoplasmic expression of lysyl oxidase-like 2 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Hum Pathol 43(7):1068–1076. https://doi.org/10.1016/j.humpath.2011.07.027
doi: 10.1016/j.humpath.2011.07.027
pubmed: 22204712
Mäki JM, Kivirikko KI (2001) Cloning and characterization of a fourth human lysyl oxidase isoenzyme. Biochem J 355(Pt 2):381–387. https://doi.org/10.1042/0264-6021:3550381
doi: 10.1042/0264-6021:3550381
pubmed: 11284725
pmcid: 1221749
Mäki JM, Tikkanen H, Kivirikko KI (2001) Cloning and characterization of a fifth human lysyl oxidase isoenzyme: the third member of the lysyl oxidase-related subfamily with four scavenger receptor cysteine-rich domains. Matrix Biology : Journal of the International Society for Matrix Biology 20(7):493–496. https://doi.org/10.1016/s0945-053x(01)00157-3
doi: 10.1016/s0945-053x(01)00157-3
pubmed: 11691589
Molnar J, Fong KS, He QP, Hayashi K, Kim Y, Fong SF, Fogelgren B, Szauter KM, Mink M, Csiszar K (2003) Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochem Biophys Acta 1647(1–2):220–224. https://doi.org/10.1016/s1570-9639(03)00053-0
doi: 10.1016/s1570-9639(03)00053-0
pubmed: 12686136
Oskarsson T (2013) Extracellular matrix components in breast cancer progression and metastasis. Breast (edinburgh, Scotland) 22(Suppl 2):S66-72. https://doi.org/10.1016/j.breast.2013.07.012
doi: 10.1016/j.breast.2013.07.012
pubmed: 24074795
Ren P, Niu X, Zhao R, Liu J, Ren W, Dai H, Chen J, Yan J, Li B, Shao Y, Bai Y, Han P (2022) Long non-coding RNA AGAP2-AS1 promotes cell proliferation and invasion through regulating miR-193a-3p/LOXL4 axis in laryngeal squamous cell carcinoma. Cell Cycle (georgetown, Tex) 21(7):697–707. https://doi.org/10.1080/15384101.2021.2016197
doi: 10.1080/15384101.2021.2016197
pubmed: 35113007
Saito H, Papaconstantinou J, Sato H, Goldstein S (1997) Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence. J Biol Chem 272(13):8157–8160. https://doi.org/10.1074/jbc.272.13.8157
doi: 10.1074/jbc.272.13.8157
pubmed: 9079631
Sebban S, Davidson B, Reich R (2009) Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. Virchows Arch 454(1):71–79. https://doi.org/10.1007/s00428-008-0694-6
doi: 10.1007/s00428-008-0694-6
pubmed: 19015874
Sebban S, Golan-Gerstl R, Karni R, Vaksman O, Davidson B, Reich R (2013) Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. Clin Exp Metastasis 30(1):103–117. https://doi.org/10.1007/s10585-012-9514-0
doi: 10.1007/s10585-012-9514-0
pubmed: 22806361
Shao J, Lu J, Zhu W, Yu H, Jing X, Wang YL, Wang X, Wang XJ (2019) Derepression of LOXL4 inhibits liver cancer growth by reactivating compromised p53. Cell Death Differ 26(11):2237–2252. https://doi.org/10.1038/s41418-019-0293-x
doi: 10.1038/s41418-019-0293-x
pubmed: 30728460
pmcid: 6889417
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Tan HY, Wang N, Zhang C, Chan YT, Yuen MF, Feng Y (2021) Lysyl oxidase-like 4 fosters an immunosuppressive microenvironment during hepatocarcinogenesis. Hepatology 73(6):2326–2341. https://doi.org/10.1002/hep.31600
doi: 10.1002/hep.31600
pubmed: 33068461
Tessari A, Palmieri D, Di Cosimo S (2013) Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmacogenomics and Personalized Medicine 7:1–19. https://doi.org/10.2147/pgpm.S53304
doi: 10.2147/pgpm.S53304
pubmed: 24403841
pmcid: 3883531
Tian M, Liu W, Jin L, Jiang X, Yang L, Ding Z, Shen Y, Peng Y, Gao D, Li L, Zhou J, Qiu S, Dai Z, Fan J, Shi Y (2015) LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis. Int J Clin Exp Pathol 8(4):3892–3900
pubmed: 26097573
pmcid: 4466960
Tse AP, Sze KM, Shea QT, Chiu EY, Tsang FH, Chiu DK, Zhang MS, Lee D, Xu IM, Chan CY, Koh HY, Wong CM, Zheng YP, Ng IO, Wong CC (2018) Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis 7(5):44. https://doi.org/10.1038/s41389-018-0052-8
doi: 10.1038/s41389-018-0052-8
pubmed: 29799025
pmcid: 5968027
Wang C, Wang J, Chen Z, Gao Y, He J (2017) Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chin J Cancer 36(1):65. https://doi.org/10.1186/s40880-017-0232-5
doi: 10.1186/s40880-017-0232-5
pubmed: 28818096
pmcid: 5561640
Wang Y, Lu Y, Xu W, Wang Y, Wu Y, Che G (2019a) Prognostic value of osteopontin expression in esophageal squamous cell carcinoma: A meta-analysis. Pathol Res Pract 215(10):152571. https://doi.org/10.1016/j.prp.2019.152571
doi: 10.1016/j.prp.2019.152571
pubmed: 31387806
Wang Y, Xing Q, Chen X, Wang J, Guan S, Chen X, Sun P, Wang M, Cheng Y (2019b) The clinical prognostic value of lrg1 in esophageal squamous cell carcinoma. Curr Cancer Drug Targets 19(9):756–763. https://doi.org/10.2174/1568009619666190204095942
doi: 10.2174/1568009619666190204095942
pubmed: 30714525
Wei Q, Li X, Zhu Z, Yu W, Qin G, Chen H, Gu Y, Zhao K, Fu X, Sun M (2019) Expression and prognostic value of FOXP1 in esophageal squamous cell carcinoma. Pathol Res Pract 215(12):152645. https://doi.org/10.1016/j.prp.2019.152645
doi: 10.1016/j.prp.2019.152645
pubmed: 31704154
Wei Z, Shan Y, Tao L, Liu Y, Zhu Z, Liu Z, Wu Y, Chen W, Wang A, Lu Y (2017) Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and decreases breast cancer metastasis. Mol Carcinog 56(10):2317–2331. https://doi.org/10.1002/mc.22686
doi: 10.1002/mc.22686
pubmed: 28574600
Weise JB, Rudolph P, Heiser A, Kruse ML, Hedderich J, Cordes C, Hoffmann M, Brant O, Ambrosch P, Csiszar K, Görögh T (2008) LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer. European Journal of Cancer (oxford, England : 1990) 44(9):1323–1331. https://doi.org/10.1016/j.ejca.2008.03.026
doi: 10.1016/j.ejca.2008.03.026
pubmed: 18499440
Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, Ng IO, Wirtz D, Semenza GL (2011) Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 108(39):16369–16374. https://doi.org/10.1073/pnas.1113483108
doi: 10.1073/pnas.1113483108
pubmed: 21911388
pmcid: 3182724
Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME, Semenza GL (2012) Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (berl) 90(7):803–815. https://doi.org/10.1007/s00109-011-0855-y
doi: 10.1007/s00109-011-0855-y
pubmed: 22231744
Wu G, Guo Z, Chang X, Kim MS, Nagpal JK, Liu J, Maki JM, Kivirikko KI, Ethier SP, Trink B, Sidransky D (2007) LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. Can Res 67(9):4123–4129. https://doi.org/10.1158/0008-5472.Can-07-0012
doi: 10.1158/0008-5472.Can-07-0012
Xie S, Liu G, Huang J, Hu HB, Jiang W (2019a) miR-210 promotes lung adenocarcinoma proliferation, migration, and invasion by targeting lysyl oxidase-like 4. J Cell Physiol 234(8):14050–14057. https://doi.org/10.1002/jcp.28093
doi: 10.1002/jcp.28093
pubmed: 30633357
Xie W, Huang P, Wu B, Chen S, Huang Z, Wang J, Sun H, Wu J, Xie L, Cheng Y, Xie W, Xu L, Chen LQ, Li E, Zou H (2019b) Clinical significance of LOXL4 expression and features of LOXL4-associated protein-protein interaction network in esophageal squamous cell carcinoma. Amino Acids 51(5):813–828. https://doi.org/10.1007/s00726-019-02723-4
doi: 10.1007/s00726-019-02723-4
pubmed: 30900087
Yeh CM, Chang LY, Lin SH, Chou JL, Hsieh HY, Zeng LH, Chuang SY, Wang HW, Dittner C, Lin CY, Lin JM, Huang YT, Ng EK, Cheng AS, Wu SF, Lin J, Yeh KT, Chan MW (2016) Epigenetic silencing of the NR4A3 tumor suppressor, by aberrant JAK/STAT signaling, predicts prognosis in gastric cancer. Sci Rep 6:31690. https://doi.org/10.1038/srep31690
doi: 10.1038/srep31690
pubmed: 27528092
pmcid: 4985659
Yilmaz M, Suer I, Karatas OF, Cansiz H, Ozen M (2016) Differential expression of LOXL4 in normal and tumour tissue samples of laryngeal squamous cell carcinoma. Clin Otolaryngol 41(3):206–210. https://doi.org/10.1111/coa.12498
doi: 10.1111/coa.12498
pubmed: 26138381
Yin H, Wang Y, Wu Y, Zhang X, Zhang X, Liu J, Wang T, Fan J, Sun J, Yang A, Zhang R (2020) EZH2-mediated epigenetic silencing of miR-29/miR-30 targets LOXL4 and contributes to tumorigenesis, metastasis, and immune microenvironment remodeling in breast cancer. Theranostics 10(19):8494–8512. https://doi.org/10.7150/thno.44849
doi: 10.7150/thno.44849
pubmed: 32754259
pmcid: 7392008
Yue J, Mulder KM (2001) Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 91(1):1–34. https://doi.org/10.1016/s0163-7258(01)00143-7
doi: 10.1016/s0163-7258(01)00143-7
pubmed: 11707292
Zhang Y, Jiang WL, Yang JY, Huang J, Kang G, Hu HB, Xie S (2019) Downregulation of lysyl oxidase-like 4 LOXL4 by miR-135a-5p promotes lung cancer progression in vitro and in vivo. J Cell Physiol 234(10):18679–18687. https://doi.org/10.1002/jcp.28508
doi: 10.1002/jcp.28508
pubmed: 30993701
Zhao X, Tang YP, Wang CY, Wu JX, Ye F (2019) Prognostic values of STAT3 and HIF-1α in esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci 23(8):3351–3357. https://doi.org/10.26355/eurrev_201904_17698
doi: 10.26355/eurrev_201904_17698
pubmed: 31081089
Zhou H, Dong J, Guo L, Wang X, Wang K, Cai X, Yang S (2019) The prognostic value of B7–H6 in esophageal squamous cell carcinoma. Sci Rep 9(1):18122. https://doi.org/10.1038/s41598-019-54731-9
doi: 10.1038/s41598-019-54731-9
pubmed: 31792298
pmcid: 6889130